- Home
- TVRD vs ECOR Comparison
TVRD vs ECOR Comparison
Compare TVRD & ECOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TVRD | ECOR |
|---|---|---|
| Founded | 2017 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 37.3M | 39.6M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | TVRD | ECOR |
|---|---|---|
| Price | $3.94 | $4.78 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 2 |
| Target Price | ★ $51.67 | $25.50 |
| AVG Volume (30 Days) | ★ 135.5K | 41.8K |
| Earning Date | 02-21-2026 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $29,835,000.00 |
| Revenue This Year | N/A | $28.61 |
| Revenue Next Year | N/A | $41.21 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 27.90 |
| 52 Week Low | $3.74 | $4.16 |
| 52 Week High | $43.65 | $19.49 |
Technical Indicators
Market Signals| Indicator | TVRD | ECOR |
|---|---|---|
| Relative Strength Index (RSI) | 34.78 | 50.40 |
| Support Level | $3.90 | $4.42 |
| Resistance Level | $4.46 | $4.96 |
| Average True Range (ATR) | 0.24 | 0.28 |
| MACD | 0.14 | 0.02 |
| Stochastic Oscillator | 14.29 | 64.62 |
Price Performance
Historical ComparisonAbout TVRD Tvardi Therapeutics Inc.
Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.
About ECOR electroCore Inc.
electroCore Inc is a commercial stage bioelectronic medicine company with a platform for non-invasive vagus nerve stimulation therapy initially focused on neurology. The company's product gammaCore is Food and Drug Administration cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, the acute treatment of pain associated with migraine headache in adult patients, and the prevention of migraine in adult patients, The use of gammaCore by adolescent patients and Treatment of hemicrania continua and paroxysmal hemicrania in adult patients.